Cardiovascular diseases (CVD) are the leading cause of death globally, posing a major public health challenge due to their increasing prevalence and complex etiology. Natural products from medicinal mushrooms have gained attention for their cardioprotective properties. To evaluate whether the aqueous extract of Lenzites betulinus can protect mononuclear cells of acute coronary syndrome (ACS) and heart failure (HF) patients from therapy-induced DNA damage and to determine its polyphenolic composition. The study included 30 healthy controls, 30 ACS and 30 HF patients. The genoprotective potential of aqueous mushroom extract at concentrations of 50, 100, 150, and 200 mg/mL was examined in vitro using the comet assay on human blood mononuclear cells. Total phenolic and flavonoid contents were determined spectrophotometrically, while polyphenolic profiling was performed using UHPLC-DAD-MS/MS. The mean level of DNA damage in treated cell cultures from healthy donors increased in a concentration-dependent manner compared with the negative control, but without statistical significance. The extract significantly reduced therapy-induced level of DNA damage in mononuclear cells of ACS and HF patients (p < 0.0005). DNA damage level was significantly higher in HF patients. In ACS patients, %DNA damage was significantly reduced at the three highest concentrations, while genetic damage index (GDI) decreased at all concentrations. In HF patients, %DNA damage decreased at the two highest concentrations, and GDI at all except the lowest. Phytochemical analysis revealed high levels of phenolics and flavonoids, with chlorogenic acid and quercetin as dominant compounds. L. betulinus possesses significant nutritional and functional value. Its rich phytochemical profile likely underlies its chemoprotective effects against therapy-induced DNA damage, suggesting potential as a natural agent for genome stability support in CVD patients.
Vukajlović et al. (Sat,) studied this question.